[Webinar] Maintaining Momentum: Applying Recent Regulatory Guidance in the Midst of the Coronavirus
COVID-19
We applaud and support the efforts of teams developing treatments for COVID-19. As a proven leader in regulatory affairs, we understand the challenges that come with crucial studies. We stand ready to help those working for answers to navigate complex regulatory issues.
Slider

Service Solutions

Cato Research, Your Reliable Partner

Cato Research (CATO) is an international regulatory and clinical contract research organization (CRO) that has been delivering successful outcomes for its clients since 1988. Through highly qualified and experienced personnel located in offices across North America, Europe, Israel, and South Africa, supported by strategic alliances with selected regional CROs, CATO offers tried-and-trusted international coverage.

CATO has the advantage of integrated regulatory, clinical, and scientific expertise. Our highly talented and experienced international team offers services from preclinical through IND (or equivalent), clinical development, and marketing approval to Phase 4 postmarketing research. Our track record includes successes across many different health products, including drugs, biologics, vaccines, cell therapies (including stem cells), nutriceuticals, medical foods, devices, and diagnostics. In terms of diseases and indications, CATO has been involved in a wide variety of projects with a dominant focus in oncology, neurology/CNS, and rare and orphan drug indications. This experience includes leadership of, and involvement in some of the most challenging and innovative products.

Therapeutic Expertise

What our Sponsors say about us...

Our CATO team has been really delivering for us.

Our CATO team has been really delivering for us. We have had a lot of Information Requests throughout the NDA review and have provided a number of submissions to CATO, very late in the day often at inopportune times, despite intensive planning from the moment of receipt. We do not wish to make a habit out of this and continue to strive to ensure there is fair and adequate time for everyone to do their job under reasonable circumstances. Our team has consistently delivered, and gone above and beyond over and over.

 

- North America Biopharmaceutical

Cato Research - International Contract Research Organization | Research Triangle Park, Durham, North Carolina
2019-05-28T13:12:27-04:00

- North America Biopharmaceutical

Our CATO team has been really delivering for us. We have had a lot of Information Requests throughout the NDA review and have provided a number of submissions to CATO, very late in the day often at inopportune times, despite intensive planning from the moment of receipt. We do not wish to make a habit out of this and continue to strive to ensure there is fair and adequate time for everyone to do their job under reasonable circumstances. Our team has consistently delivered, and gone above and beyond over and over.  

Congratulations Team! Another Approval!

I would like to thank the Cato Research team for their contributions to this successful application including the advice, guidance and participation in the Type A meeting we had with the FDA last year after the CRL was issued.

I have shared the approval letter with the Executives.

- A Canadian Innovative Drug Company

Cato Research - International Contract Research Organization | Research Triangle Park, Durham, North Carolina
2019-07-26T11:07:21-04:00

- A Canadian Innovative Drug Company

I would like to thank the Cato Research team for their contributions to this successful application including the advice, guidance and participation in the Type A meeting we had with the FDA last year after the CRL was issued. I have shared the approval letter with the Executives.
0
0
Cato Research - International Contract Research Organization | Research Triangle Park, Durham, North Carolina

Upcoming Events

No event found!
Load More

Cato Research Blog

  • New FDA Gudiances for June 2020 and Upcoming...
    by Cato Research on July 5, 2020 at 9:53 pm

    By Sheila Plant, PhD, MHS, RAC, Senior Director, Regulatory Affairs at CATO SMS    Special Interest Guidances/Information Date Posted Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry – Final Guidance 30 Jun 2020 Review and Update of Device Establishment […]

  • New FDA Gudiances for May 2020 and Upcoming...
    by Cato Research on June 8, 2020 at 8:06 pm

    By Zachary Swan, PhD, RAC, Associate Director, Regulatory Affairs at CATO SMS    Special Interest Guidances/Information Date Posted Submission of Plans for Cigarette Packages and Cigarette Advertisements (Revised) – Final Guidance 28 May 2020 Required Warnings for Cigarette Packages and […]

Twitter @CatoResearch

LinkedIn Cato Research

Facebook @catoresearch

Searching for something else?